PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,975,516 | -7.3% | 64,391 | +21.1% | 0.10% | -6.8% |
| Q2 2023 | $2,131,444 | -11.2% | 53,193 | -9.6% | 0.10% | -20.8% |
| Q1 2023 | $2,401,138 | +138.0% | 58,837 | +125.1% | 0.13% | +113.1% |
| Q4 2022 | $1,009,072 | -56.4% | 26,135 | -39.9% | 0.06% | -59.6% |
| Q3 2022 | $2,313,000 | -5.6% | 43,484 | +3.5% | 0.15% | +14.4% |
| Q2 2022 | $2,450,000 | -33.3% | 42,032 | -12.7% | 0.13% | -17.5% |
| Q1 2022 | $3,673,000 | -50.3% | 48,124 | -60.8% | 0.16% | -54.2% |
| Q4 2021 | $7,387,000 | +72.7% | 122,766 | +60.7% | 0.35% | +44.2% |
| Q3 2021 | $4,277,000 | +20.3% | 76,381 | +20.5% | 0.24% | -0.8% |
| Q2 2021 | $3,555,000 | -16.6% | 63,398 | +4.2% | 0.24% | -60.4% |
| Q1 2021 | $4,265,000 | +52.3% | 60,845 | +55.3% | 0.62% | +91.3% |
| Q4 2020 | $2,800,000 | – | 39,184 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tamarack Advisers, LP | 360,000 | $21,845,000 | 6.19% |
| Gagnon Advisors, LLC | 213,217 | $12,938,000 | 4.92% |
| GAGNON SECURITIES LLC | 499,333 | $30,300,000 | 4.30% |
| Spyglass Capital Management LLC | 2,117,673 | $128,500,000 | 2.86% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 646,530 | $39,231,000 | 2.30% |
| Paulson & Co. | 1,273,161 | $77,255,000 | 1.85% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 212,112 | $12,871,000 | 1.44% |
| Tygh Capital Management, Inc. | 152,332 | $9,244,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,147,000 | $69,600,000 | 1.24% |
| Rock Springs Capital Management LP | 1,025,000 | $62,197,000 | 1.23% |